Stivarga 40 MG tablet 21S
Ended Awarded Last action
- Contract number
- SPE2DR26FHNU1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,939
Award facts
- Contract value 100% obligated
- $16,939.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $16,939.20 to DMS Pharmaceutical Group Inc. for 21 tablets of Stivarga 40 mg on January 6, 2026, with completion scheduled for January 7, 2026. Stivarga is an oncology medication used in cancer treatment. The contract is structured as a firm fixed-price delivery order with no set-aside designation, issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, serving as a critical supplier of pharmaceutical products and medical consumables to the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award IDC established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, awarded in November 2025 with a ceiling value of $499,999,999 and extending through December 31, 2036. The PPV-G GEN V program is a $30.3 billion acquisition strategy designed to provide the Department of Defense with a reliable supply of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide. As a regional prime vendor contractor under this program, DMS Pharmaceutical Group has demonstrated consistent performance across diverse therapeutic categories, positioning it as a key supplier for the federal military medical system's recurring pharmaceutical requirements.
Quick answers
Who was awarded contract SPE2DR26FHNU1?
SPE2DR26FHNU1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FHNU1 worth?
The government has obligated $16,939 on SPE2DR26FHNU1.
Is contract SPE2DR26FHNU1 an order under another contract?
Yes. SPE2DR26FHNU1 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNU1 competed?
The extent of competition for SPE2DR26FHNU1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award